Friday, December 10, 2021, Atlanta, GA, 7:00 PM – 9:00 PM Eastern Time

What Clinicians Want To Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Part 4 of a 4-Part Series)

A Friday Satellite Symposium and Virtual Event Preceding the 63rd ASH Annual Meeting

Location
Omni Atlanta Hotel at CNN Center
190 Marietta St NW
Atlanta, GA 30303
Hotel Phone: (404) 659-0000

Program Schedule — Eastern Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
International Ballroom (E-F) - North Tower (M2 Floor)


This event will be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Atlanta, GA preregistration is required as seating is limited.  
 
Faculty
Alice S Mims, MD, MSCR
Acute Leukemia Clinical Research Director
Associate Professor, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine
Member, Leukemia Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania


Richard M Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Dana-Farber Cancer Institute
Boston, Massachusetts

Geoffrey L Uy, MD
Professor of Medicine
Division of Oncology
Washington University School of Medicine
St Louis, Missouri

Moderator
Harry Paul Erba, MD, PhD
Director, Leukemia Program
Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina


This activity is supported by educational grants from Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc and Servier Pharmaceuticals LLC.
Program Schedule — Eastern Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Front-Line Treatment for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Therapy

MODULE 2: Induction and Maintenance Options for Younger Patients with AML with No Targetable Mutations

MODULE 3: Optimal Treatment Approaches for AML with Targetable Mutations

MODULE 4: Management of Secondary AML; New Directions in AML Care

MODULE 5: Current and Future Management Approaches for Myelodysplastic Syndromes

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
  • Appreciate the FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML unfit for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
  • Review Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and consider how this novel strategy can be applied in current clinical management.
  • Reflect on available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Develop an understanding of the mechanisms of action of, recent data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or 2 mutation.
  • Assess the FDA-approved indications for CPX-351 for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
  • Formulate a treatment algorithm for patients with lower- and higher-risk myelodysplastic syndromes (MDS), considering patient- and disease-related factors, including cytogenetic abnormalities.
  • Recognize the recent FDA approval of the combination of decitabine and cedazuridine for patients with intermediate- and high-risk MDS, and identify patients for whom treatment with this novel approach may be appropriate.
  • Describe the biologic rationale for and mechanism of action of luspatercept in the treatment of anemia secondary to MDS, and appraise how this agent can be appropriately integrated into clinical practice.
  • Recall promising agents and strategies under investigation for AML and MDS, and counsel appropriately selected patients regarding clinical trial enrollment.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

FACULTYDr Uy has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr MimsAdvisory Committee: AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Kura Oncology, Syndax Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Aptevo Therapeutics, Astex Pharmaceuticals, Kartos Therapeutics, Karyopharm Therapeutics, Leukemia & Lymphoma Society, Plexxikon Inc, Xencor; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc; Other: Leukemia & Lymphoma Society — Senior Medical Director for the Beat AML study. Dr PerlAdvisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Syndax Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AbbVie Inc, Astellas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Beat AML LLC, Leukemia & Lymphoma Society. Dr StoneConsulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Aprea Therapeutics, Arog Pharmaceuticals Inc, BerGenBio ASA, Boston Pharmaceuticals, Bristol-Myers Squibb Company, ElevateBio, Foghorn Therapeutics, GEMoaB, GlaxoSmithKline, Innate Pharma, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Onconova Therapeutics Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc.

MODERATORHarry Paul Erba, MD, PhDAdvisory Committee and Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Daiichi Sankyo Inc, FORMA Therapeutics, Forty Seven Inc, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, PTC Therapeutics; Independent Review Committee: AbbVie Inc; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc and Servier Pharmaceuticals LLC.

Omni Atlanta Hotel at CNN Center
190 Marietta St NW
Atlanta, GA 30303
Hotel Phone: (404) 659-0000

Meeting Room
International Ballroom (E-F) - North Tower (M2 Floor)

Directions
The Omni Atlanta Hotel at CNN Center is conveniently located within walking distance of the Georgia World Congress Center, where the ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.

There is no fee to participate in this program or live webcast of this event.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.